牛牛AI助理已提取核心訊息
Merck & Co. Inc. officer Steven C. Mizell is set to sell 50,694 shares of the company's common stock, with an aggregate market value of approximately $6,420,349.48, on February 2, 2024. The shares to be sold were acquired through various transactions, including restricted stock vesting and the exercise of options under a registered plan, with acquisition dates ranging from May 4, 2021, to February 2, 2024. The most recent acquisition involved the exercise of options on February 2, 2024, where 824 shares were purchased with cash. No sales of securities have been reported in the past three months prior to the notice date.
Merck & Co. Inc. officer Steven C. Mizell is set to sell 50,694 shares of the company's common stock, with an aggregate market value of approximately $6,420,349.48, on February 2, 2024. The shares to be sold were acquired through various transactions, including restricted stock vesting and the exercise of options under a registered plan, with acquisition dates ranging from May 4, 2021, to February 2, 2024. The most recent acquisition involved the exercise of options on February 2, 2024, where 824 shares were purchased with cash. No sales of securities have been reported in the past three months prior to the notice date.
默沙東公司公司高管史蒂芬·米澤爾定於2024年2月2日出售該公司50,694股普通股，總市值約爲6,420,349.48美元。待售股票是通過各種交易收購的，包括限制性股票歸屬和根據註冊計劃行使期權，收購日期從2021年5月4日到2024年2月2日不等。最近的收購涉及2024年2月2日行使期權，其中824股以現金購買。在通知日期之前的過去三個月中，沒有報告任何證券的銷售情況。
默沙東公司公司高管史蒂芬·米澤爾定於2024年2月2日出售該公司50,694股普通股，總市值約爲6,420,349.48美元。待售股票是通過各種交易收購的，包括限制性股票歸屬和根據註冊計劃行使期權，收購日期從2021年5月4日到2024年2月2日不等。最近的收購涉及2024年2月2日行使期權，其中824股以現金購買。在通知日期之前的過去三個月中，沒有報告任何證券的銷售情況。
有用
沒用